{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:34:01Z","timestamp":1783636441586,"version":"3.55.0"},"reference-count":23,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The most commonly used regimens fail to eradicate Helicobacter pylori (H. pylori) infection in 5\u201310% of patients. Those not cured with treatments based on amoxicillin, clarithromycin, nitroimidazoles, fluoroquinolones, bismuth or tetracycline have no other conventional options thereafter. In this prospective long-term monocentric study, patients who failed to eradicate H. pylori following treatment with all conventional antibiotics were included. All subjects were treated with rifabutin 150 mg, amoxicillin 1 g and a standard dose of proton pump inhibitor, twice daily for 14 days. A negative 13C-urea breath test was used four weeks after treatment completion as an index of H. pylori eradication. Three hundred and two patients were included. Fifty-four percent (164\/302) had peptic ulcer disease while 45.7% (138\/302) had gastritis or functional dyspepsia. Per-protocol eradication and intention-to-treat eradication were achieved in 72.7% and 71.5%, respectively. A univariate analysis showed that gender, ethnic background, smoking habits and familial history of gastric diseases were not predictive factors of response, while with multiple logistic regression analysis, the ethnic background (Italian) predicted a poor response in the second period of the study (2010\u20132017). In conclusion, this study on a large cohort of very difficult-to-treat patients showed that rifabutin-based rescue therapy is an acceptable and safe strategy after multiple eradication failures with conventional antibiotics.<\/jats:p>","DOI":"10.3390\/jcm8020199","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T11:51:12Z","timestamp":1549453872000},"page":"199","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-3087","authenticated-orcid":false,"given":"Davide Giuseppe","family":"Ribaldone","sequence":"first","affiliation":[{"name":"Department of Surgical Sciences, University of Turin, 10123 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6070-6716","authenticated-orcid":false,"given":"Sharmila","family":"Fagoonee","sequence":"additional","affiliation":[{"name":"Institute of Biostructure and Bioimaging (CNR) c\/o Molecular Biotechnology Center, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Astegiano","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, Molinette Hospital, 10123 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Durazzo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10123 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Morgando","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, Molinette Hospital, 10123 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Sprujevnik","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, Molinette Hospital, 10123 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1486-3654","authenticated-orcid":false,"given":"Chiara","family":"Giordanino","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, Molinette Hospital, 10123 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Baronio","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, Maria Vittoria Hospital, 10100 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"De Angelis","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, Molinette Hospital, 10123 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5310-4143","authenticated-orcid":false,"given":"Giorgio Maria","family":"Saracco","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, Molinette Hospital, 10123 Turin, Italy"},{"name":"Department of Medical Sciences, University of Turin, 10123 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-0649","authenticated-orcid":false,"given":"Rinaldo","family":"Pellicano","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, Molinette Hospital, 10123 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"ref_1","first-page":"304","article-title":"A 2016 panorama of Helicobacter pylori infection: Key messages for clinicians","volume":"58","author":"Pellicano","year":"2016","journal-title":"Panminerva. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e12411","DOI":"10.1111\/hel.12411","article-title":"Helicobacter pylori infection and extragastric diseases in 2017","volume":"22","author":"Ianiro","year":"2017","journal-title":"Helicobacter"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","article-title":"Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption","volume":"62","author":"Coenen","year":"2013","journal-title":"Gut"},{"key":"ref_4","first-page":"280","article-title":"Benign and malignant gastroduodenal diseases associated with Helicobacter pylori: A narrative review and personal remarks in 2018","volume":"64","year":"2018","journal-title":"Minerva. Gastroenterol. Dietol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.3748\/wjg.v23.i18.3367","article-title":"Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance","volume":"23","author":"Cosme","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","article-title":"Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, non-inferiority, phase 3 trial","volume":"377","author":"Malfertheiner","year":"2011","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1128\/AAC.05437-11","article-title":"Helicobacter pylori resistance to rifabutin in the last 7 years","volume":"55","author":"Nishizawa","year":"2011","journal-title":"Antimcrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2011.04937.x","article-title":"Review article: Rifabutin in the treatment of refractory Helicobacter pylori infection","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e12410","DOI":"10.1111\/hel.12410","article-title":"Treatment of Helicobacter pylori infection 2017","volume":"22","author":"Lamarque","year":"2017","journal-title":"Helicobacter"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.23736\/S1121-421X.18.02483-2","article-title":"Management of Helicobacter pylori in Piedmont, Italy","volume":"64","author":"Ribaldone","year":"2018","journal-title":"Minerva. Gastroenterol. Dietol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/MEG.0000000000000960","article-title":"Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection","volume":"29","author":"Costa","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"I40","DOI":"10.1136\/gut.45.2008.i40","article-title":"Treatment after failure: The problem of non-responders","volume":"45","author":"Huang","year":"1999","journal-title":"Gut"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1365-2036.2000.00719.x","article-title":"Rifabutin-based \u201crescue therapy\u201d for Helicobacter pylori infected patients after failure of standard regimens","volume":"14","author":"Perri","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1365-2036.2001.00909.x","article-title":"Rifabutin-based Helicobacter pylori eradication \u201crescue therapy\u201d","volume":"15","author":"Canducci","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2036.2012.05053.x","article-title":"Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/hel.12296","article-title":"Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third-line treatment of Helicobacter pylori infection. Two pilot studies","volume":"21","author":"Ciccaglione","year":"2016","journal-title":"Helicobacter"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2036.2000.00685.x","article-title":"Efficacy of a multi step strategy for Helicobacter pylori eradication","volume":"14","author":"Gasbarrini","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2036.2007.03573.x","article-title":"Empirical rescue therapy after Helicobacter pylori treatment failure: A 10-year single-centre study of 500 patients","volume":"27","author":"Gisbert","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1128\/AAC.44.6.1713-1715.2000","article-title":"Mutations of four distinct regions of the rpoB gene can reduce the susceptibility of Helicobacter pylori to rifamycins","volume":"44","author":"Heep","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","first-page":"e12451","article-title":"Molecular characterization of Helicobacter pylori resistance to rifamycins","volume":"22","author":"Hays","year":"2017","journal-title":"Helicobacter"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1523-5378.2005.00324.x","article-title":"Helicobacter pylori rescue therapy after failure of two eradication treatments","volume":"10","author":"Gisbert","year":"2005","journal-title":"Helicobacter"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"198","DOI":"10.23736\/S0031-0808.16.03284-5","article-title":"Helicobacter pylori 2017: Revitalized therapies for an ever-challenging bug","volume":"59","author":"Actis","year":"2017","journal-title":"Panminerva. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/2\/199\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:31:21Z","timestamp":1760185881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/2\/199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["jcm8020199"],"URL":"https:\/\/doi.org\/10.3390\/jcm8020199","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]}}}